1616632-77-9Cc1ccccc1CN1C(=O)C2=C(CCN(Cc3ccccc3)C2)N2CCN=C12VLULRUCCHYVXOH-UHFFFAOYSA-NDordaviprone is an organic heterotricyclic compound that is 2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one substituted by 2-methylbenzyl and benzyl groups at positions 4 and 7, respectively. It is a selective antagonist of the dopamine receptor D2 and an allosteric agonist of mitochondrial protease caseinolytic protease P. It has a role as a dopamine receptor D2 antagonist, an antineoplastic agent and an apoptosis inducer. It is a member of benzenes, an organic heterotricyclic compound and a member of toluenes.
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Dordaviprone is a drug with anti-tumour activity: It exhibited anti-tumour activity in cell-based assays and in vivo models of H3 K27M-mutant diffuse glioma. Dordaviprone causes a concentration-dependent QTc interval prolongation. At 1.2 times the maximum recommended dose, the estimated mean QTcF change was 11.8 msec (90% CI: 9.8, 13.7). The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of dordaviprone have not been fully characterized.
Dordaviprone is a protease activator of the mitochondrial caseinolytic protease P (ClpP), a mitochondrial serine protease. Diffuse midline gliomas harboring an H3 K27M mutation are associated with the loss of H3 K27 trimethylation. In vitro, dordaviprone induced apoptosis and altered mitochondrial metabolism leading to restored histone H3 K27 trimethylation in H3 K27M-mutant diffuse glioma models. Dordaviprone activates ATF4 and induces endoplasmic reticulum (ER) stress response or integrated stress response (ISR). Dordaviprone also inhibits the dopamine D2 receptor, which are often overexpressed in multiple cancers, including glioblastoma.
9U35A31JAI
DORDAVIPRONE
Established Pharmacologic Class [EPC] - Protease Activator
Mechanisms of Action [MoA] - Protease Activators
Dordaviprone is a Protease Activator. The mechanism of action of dordaviprone is as a Protease Activator.
1616632-77-9DTXSID701356572CHEMBL4297310CHEBI:232328Dordaviprone maximum concentration (Cmax) is 2.8 mcg/mL (42%), and total systemic exposure (AUC) is 23 hr x mcg/mL (48%). Dordaviprone Cmax and AUC increased in a dose proportional manner over the dose range of 125 to 625 mg. Dordaviprone median (min, max) time to maximum plasma concentration (Tmax) is 1.4 hours (0.5, 5.6 hours). Dordaviprone Cmax decreased by 40% with no change on AUC following administration with a high-fat meal (800 to 1,000 calories, 50% fat).
Following a single dose of radiolabeled dordaviprone, about 70% of the dose was recovered in urine and 20% in feces with no notable unchanged dordaviprone in urine or feces.
Dordaviprone apparent (oral) volume of distribution is 450 L (40%). The median blood-to-plasma ratio is 0.67 in vitro. Dordaviprone crosses the blood-brain barrier.
The apparent clearance is approximately 27 L/hr (48%).
DescriptionTIC10 induces the expression of TNF-related apoptosis-inducing ligand (TRAIL) at 1-5 μM in a p53-independent manner. It is orally active, stable, and crosses the blood-brain barrier. The induction of TRAIL results from dual inhibition of Akt and ERK1/2 combined with nuclear translocation of the transcription factor FOXO3a. TIC10 suppresses the growth of orthotopic human glioblastoma multiforme tumors in mice.
Uses7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one is used in biological studies for structure confirmation and pharmacophore reassignment for induction of immunosurveillance cytokine TRAIL in macrophages. The structure of this compound was misassigned for many years as H291055. The resolution of this issue was recently highlighted in Chemical and Engeneering News 92(23) 32 (2014).